FDMT 10-Q: SEC filing

4D Molecular Therapeutics

Filed with the SEC on Nov 12, 2026 · accession 0001193125-26-458477

FDMT filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

4D Molecular Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and business updates.

For details, click here →How to read a 10-Q →

Key details

Filer4D Molecular Therapeutics, Inc.

Collaboration partnerOtsuka Pharmaceutical Company Ltd.

Funding partnerCystic Fibrosis Foundation

LenderHercules Capital, Inc.

Agreement counterpartyAevitas Therapeutics Inc.

✦ Ask GOAX AI about this filing — what it means for FDMT, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for FDMT?

Click here

Frequently asked questions

What did FDMT file with the SEC on Nov 12, 2026?

FDMT filed a 10-Q (SEC filing). 4D Molecular Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and business updates.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other FDMT SEC filings

Get alerts when FDMT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

FDMT overview FDMT analysis FDMT news Latest SEC filings